Clinical Trial Update: Figitumumab Combined With Pegvisomant For Advanced Solid Tumors [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial evaluating the combination of figitumumab with pegvisomant for advanced solid tumors was terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Colorectal Cancer
• Lung Cancer
• Prostate Cancer
• Soft Tissue Sarcoma

Drugs mentioned

• Figitumumab (figitumumab)
• Pegvisomant (Somavert) (pegvisomant)

Snippet

Sponsor: Pfizer | Conditions: Colorectal Neoplasms, Lung Neoplasms | Phase 1 | Status: TERMINATED | Results posted: 2013-12-13